Tekla Life Sciences Investors
HQL · NYSE
3/31/2025 | 9/30/2024 | 3/31/2024 | 9/30/2023 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$47 | – | – | $11 |
| Dep. & Amort. | $0 | – | – | $0 |
| Deferred Tax | $0 | – | – | $0 |
| Stock-Based Comp. | $0 | – | – | $0 |
| Change in WC | -$0 | – | – | $0 |
| Other Non-Cash | $46 | – | – | -$11 |
| Operating Cash Flow | -$1 | – | – | $0 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | $0 | – | – | $0 |
| Net Acquisitions | $0 | – | – | $0 |
| Inv. Purchases | -$157 | – | – | $0 |
| Inv. Sales/Matur. | $162 | – | – | $0 |
| Other Inv. Act. | $0 | – | – | $0 |
| Investing Cash Flow | $4 | – | – | $0 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | – | – | $0 |
| Stock Issued | $0 | – | – | $0 |
| Stock Repurch. | $0 | – | – | $0 |
| Dividends Paid | $0 | – | – | $0 |
| Other Fin. Act. | -$8 | – | – | $0 |
| Financing Cash Flow | -$8 | – | – | $0 |
| Forex Effect | $5 | – | – | $0 |
| Net Chg. in Cash | $0 | – | – | $0 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $0 | – | – | $0 |
| End Cash | $0 | – | – | $0 |
| Free Cash Flow | -$1 | – | – | $0 |